TrialBMJ (Clinical research ed.)2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Yunfei Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.